← 返回

伴纤维基质形态的三级淋巴结构影响基底细胞癌的抗肿瘤免疫

英文原题:Tertiary lymphoid structures accompanied by fibrillary matrix morphology impact anti-tumor immunity in basal cell carcinomas.

查看英文原题

Tertiary lymphoid structures accompanied by fibrillary matrix morphology impact anti-tumor immunity in basal cell carcinomas.

PubMed 2022/10/27(内容时间) Front Med (Lausanne) Q1 · IF 3.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

三级淋巴结构(TLS)是一种特殊的淋巴组织形成,可在慢性炎症、自身免疫和癌症部位形成局部T细胞与B细胞储库。多种癌症中,TLS存在与免疫检查点阻断疗法应答改善及总体结局较好相关,但其在基底细胞癌(BCC)中的预后价值尚未研究。

本研究通过分析TLS发生率和成熟程度与抗肿瘤免疫结局(包括TIL(肿瘤浸润淋巴细胞)[TIL]及肿瘤杀伤)的关系,评估TLS的预后影响。在30例不同BCC样本中,伴有结节成分的肿瘤更常出现TLS;成熟度较高的原发TLS与TIL计数相关。对肿瘤周围纤维状基质的分析发现,不同基质形态与较高TIL计数显著相关,且可解释不同TLS成熟阶段内TIL分布的异质性。

具体而言,TIL计数较高的肿瘤周围纤维长度增加、基质孔隙度增加,而纤维密度和排列一致性降低。鉴于诱导TLS形成作为治疗干预的研究兴趣以及TLS已证实的预后价值,仍需进一步研究可能妨碍TLS在肿瘤微环境中驱动抗肿瘤免疫的因素。这些结果初步揭示,未来应将可能阻碍TLS形成或有效发挥作用的基质特征纳入免疫治疗应答研究。

展开英文摘要原文

Tertiary lymphoid structures (TLS) are specialized lymphoid formations that serve as local repertoire of T- and B-cells at sites of chronic inflammation, autoimmunity, and cancer. While presence of TLS has been associated with improved response to immune checkpoint blockade therapies and overall outcomes in several cancers, its prognostic value in basal cell carcinoma (BCC) has not been investigated.

Herein, we determined the prognostic impact of TLS by relating its prevalence and maturation with outcome measures of anti-tumor immunity, namely tumor infiltrating lymphocytes (TILs) and tumor killing. In 30 distinct BCCs, we show the presence of TLS was significantly enriched in tumors harboring a nodular component and more mature primary TLS was associated with TIL counts.

Moreover, assessment of the fibrillary matrix surrounding tumors showed discrete morphologies significantly associated with higher TIL counts, critically accounting for heterogeneity in TIL count distribution within TLS maturation stages. Specifically, increased length of fibers and lacunarity of the matrix with concomitant reduction in density and alignment of fibers were present surrounding tumors displaying high TIL counts.

Given the interest in inducing TLS formation as a therapeutic intervention as well as its documented prognostic value, elucidating potential impediments to the ability of TLS in driving anti-tumor immunity within the tumor microenvironment warrants further investigation. These results begin to address and highlight the need to integrate stromal features which may present a hindrance to TLS formation and/or effective function as a mediator of immunotherapy response.

论文信息

作者
Byers C、Gill M、Kurtansky NR、Alessi-Fox C、Harman M、Cordova M、Gonzalez S、Guitera P
第一作者单位
The Institute for Experiential AI, Roux Institute, Northeastern University, Portland, ME, United States.United States
通讯作者单位
Memorial Sloan Kettering Cancer Center, New York, NY, United States.United States
期刊
Frontiers in medicine2022
原文标识
PubMed 36388913 · DOI 10.3389/fmed.2022.981074